All In Biotech

Drug Trial Radar · NCT07224360

Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)

Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

63

Planned (sponsor's estimate)

Start

Feb 2, 2026

Primary completion

Aug 15, 2028

Study completion Aug 15, 2028

Sponsor

Lead sponsor
CSL BehringIndustry
Sponsor type
Industry
First posted
Nov 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2a, global, multicenter, randomized, double-blind, placebo-controlled study investigating the safety of anumigilimab administered subcutaneously (SC) at the maximum tolerated dose (MTD) in adult participants with SCD. The primary aim of the study is to assess the safety of anumigilimab in participants with SCD. Participants will be treated for 64 weeks: for 12 weeks in the dose escalation period, where the dose will be escalated to each participant's individual MTD; and for 52 weeks at the MTD in the maintenance period.

Conditions

  • Sickle Cell Disease

Interventions

  • AnumigilimabBiological

    Participants will receive anumigilimab, escalated to a maximum dose guided by absolute neutrophil count (ANC) and safety concerns.

  • PlaceboDrug

    Volume matched saline will be administered SC.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Treatment Emergent Adverse Events (TEAEs), Overall and by severity, seriousness and relationship to Investigational Product (IP)Time frame: From baseline up to Week 75
  2. Percentage of participants with TEAEs Overall and by severity, seriousness and relationship to IPTime frame: From baseline up to Week 75
  3. Number of participants with Adverse Events of Special Interest (AESI)Time frame: From baseline up to Week 75
  4. Percentage of participants with AESITime frame: From baseline up to Week 75
  5. Number of participants with clinically relevant changes from baseline in laboratory assessments and vital signsTime frame: From baseline up to Week 75
  6. Percentage of participants with clinically relevant changes from baseline in laboratory assessments and vital signsTime frame: From baseline up to Week 75

Locations

38 sites in 7 countries. Site status is shown where the registry gives one.

  • UAMS Medical Center

    Little Rock, Arkansas · Recruiting

  • University of California Irvine

    Orange, California · Recruiting

  • The Foundation for Sickle Cell Disease

    Hollywood, Florida · Recruiting

  • Arthur M. Blank Hospital- Children's Healthcare of Atlanta

    Atlanta, Georgia · Recruiting

  • Center for Cancer and Blood Disorders

    Bethesda, Maryland · Recruiting

  • Boston Medical Center

    Boston, Massachusetts · Recruiting

  • University of Minnesota

    Minneapolis, Minnesota · Recruiting

  • Southern Specialty Research

    Flowood, Mississippi · Recruiting

  • NYC Health + Hospitals/Queens

    Jamaica, New York · Recruiting

  • Columbia University Medical Center

    New York, New York · Recruiting

  • Jacobi Medical Center

    The Bronx, New York · Recruiting

  • Ohio State University

    Columbus, Ohio · Recruiting

  • UT Physicians Comprehensive Adult Sickle Cell Center

    Houston, Texas · Recruiting

  • Virginia Commonwealth University

    Richmond, Virginia · Recruiting

  • CHU Saint-Pierre

    Brussels, Belgium · Recruiting

  • UZ Antwerpen

    Edegem, Antwerp, Belgium · Recruiting

  • CHU de Nantes, Hotel-Dieu

    Nantes, France · Recruiting

  • CHU de Rouen-Hôpital Charles-Nicolle

    Rouen, France · Recruiting

  • Institut Universitaire du Cancer de Toulouse

    Toulou, France · Recruiting

  • AP-HM Hôpital de La Timone

    Marseille, Bouches-du-Rhône, France · Recruiting

  • IRCCS Istituto Giannina Gaslini

    Genoa, Italy · Recruiting

  • Fondazione IRCCS San Gerardo dei Tintori

    Monza, Italy · Recruiting

  • AORN Antonio Cardarelli

    Naples, Italy · Recruiting

  • IRCCS Bambino Gesù Children's Hospital

    Rome, Italy · Recruiting

  • AOUI Verona and University of Verona

    Verona, Italy · Recruiting

  • Azienda Ospedaliero-Universitaria di Ferrara - Arcispedale Sant' Anna

    Cona, Ferrara, Italy · Recruiting

  • Amsterdam UMC - VUmc

    Amsterdam, North Holland, Netherlands · Recruiting

  • Acibadem Adana Hastanesi

    Adana, Turkey (Türkiye) · Recruiting

  • Hacettepe University Medical Faculty

    Ankara, Turkey (Türkiye) · Recruiting

  • VM Medical Park Mersin Hospital

    Mezitli, Mersin, Turkey (Türkiye) · Recruiting

  • Mersin University Medical Faculty

    Yenişehir, Mersin, Turkey (Türkiye) · Recruiting

  • Royal Liverpool University Hospital

    Liverpool, United Kingdom · Recruiting

  • The Royal London Hospital

    London, United Kingdom · Recruiting

  • Central Middlesex Hospital

    London, United Kingdom · Recruiting

  • Guy's Hospital

    London, United Kingdom · Recruiting

  • St George's University Hopsitals NHS Foundation Trust

    London, United Kingdom · Recruiting

  • Hammersmith Hospital Imperial College Healthcare NHS Trust

    London, United Kingdom · Recruiting

  • Manchester Royal Infirmary

    Manchester, England, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.